|
|
| Product Name: | OSAJIN | | Synonyms: | OSAJIN;5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one;5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one;OSAJIN(RG);5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-butenyl)-4H,8H-pyrano[2,3-f]chromen-4-one;4H,8H-Benzo[1,2-b:3,4-b']dipyran-4-one,5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-buten-1-yl)-;NSC 21565;CID 95168 | | CAS: | 482-53-1 | | MF: | C25H24O5 | | MW: | 404.46 | | EINECS: | | | Product Categories: | | | Mol File: | 482-53-1.mol |  |
| | OSAJIN Chemical Properties |
| Melting point | 189° (uncorr), 193° (corr) | | Boiling point | 632.3±55.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | powder | | pka | 7.00±0.40(Predicted) | | color | Yellow | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | Cosmetics Ingredients Functions | ANTIOXIDANT | | InChI | 1S/C25H24O5/c1-14(2)5-10-17-21(27)20-22(28)19(15-6-8-16(26)9-7-15)13-29-24(20)18-11-12-25(3,4)30-23(17)18/h5-9,11-13,26-27H,10H2,1-4H3 | | InChIKey | DCTLJGWMHPGCOS-UHFFFAOYSA-N | | SMILES | C\C(C)=C\Cc1c(O)c2C(=O)C(=COc2c3C=CC(C)(C)Oc13)c4ccc(O)cc4 |
| Hazard Codes | N | | Risk Statements | 50 | | Safety Statements | 61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1
Aquatic Chronic 1 |
| | OSAJIN Usage And Synthesis |
| Uses | Osajin is an inhibitor of carbonic anhydrase I and II isoenzymes for therapeutic application such as the treatment of glaucoma. | | Definition | ChEBI: Osajin is a member of isoflavanones. | | in vivo | Osajin and pomiferin attenuates the myocardial dysfunction provoked by ischemia reperfusion. This is confirmed by an increase in both antioxidant enzyme values and total antioxidant activity. The cardioprotection provided by osajin and pomiferin treatment results from the suppression of oxidative stress and this correlates with improved ventricular function[3]. | | target | P450 (e.g. CYP17) | Bcl-2/Bax | Caspase |
| | OSAJIN Preparation Products And Raw materials |
|